Evaluation of a somatostatin analog in the treatment of lymphoproliferative disorders: Results of a phase II North Central Cancer Treatment Group trial

Thomas E. Witzig, Louis Letendre, James Gerstner, Georgene Schroeder, James A. Mailliard, Gerardo Colon-Otero, Robert F. Marschke, Harold E. Windschitl

Research output: Contribution to journalArticle

33 Scopus citations

Abstract

Purpose: Malignant cells from non-Hodgkin's lymphomas (NHL) have been shown to express the somatostatin receptor on their cell surface and most NHL are visible on somatostatin radioscintigraphy scans. This provided the rationale to conduct a phase II trial of a somatostatin analog in patients with B- and T-cell lymphoproliferative disorders. Patients and Methods: Sixty-one patients with measurable or assessable lymphoproliferative disorders (31 stage III or IV low-grade NHL; 21 chronic lymphocytic leukemia [CLL]; and nine cutaneous T-cell NHL [CTCL]) were enrolled. Patients were treated with somatostatin 150 μg subcutaneously (SQ) every 8 hours for 1 month. Patients with stable or responding disease received 2 additional months of therapy; those who responded after 3 months were treated for an additional ≥ 3 months. Results: Sixty patients were assessable for toxicity and 56 for response. There were no complete remissions. In the low-grade NHL group, 36% (10 of 28 patients; 95% confidence interval [CI], 19% to 56%) had a partial remission. Forty-four percent (four of nine; 95% CI, 14% to 79%) of patients with CTCL had a partial response. No patients with CLL had a partial remission. Among 45 patients with stable disease or a partial remission, the mean time to progression (TTP) was 10.9 months (median, 6.2; range, 1.6 to 48.5). The drug was well tolerated, with the most common side effects being diarrhea and hyperglycemia. Conclusion: Somatostatin at a dose of 150 μg every 8 hours is well tolerated and has activity in low-grade NHL.

Original languageEnglish (US)
Pages (from-to)2012-2015
Number of pages4
JournalJournal of Clinical Oncology
Volume13
Issue number8
DOIs
StatePublished - Aug 1995

    Fingerprint

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this